Filing Flows › Emergent BioSolutions (EBS) › Free cash flow
Emergent BioSolutions (EBS) free cash flow by quarter
Emergent BioSolutions' free cash flow was $96.8M in Q3 2026 (third quarter 2026), +79% from Q2 2026. Over the last 4 quarters it ranged from $54.0M (Q2 2026) to $104M (Q2 2025).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $96.8M | +79% | — |
| Q2 2026 | $54.0M | -27% | -48% |
| Q4 2025 | $73.8M | -29% | — |
| Q2 2025 | $104M | — | — |
Q3 2026 at a glance
Emergent BioSolutions, Q3 2026: revenue $110M (-52% year over year), operating margin -33.9%, net loss $32.7M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
Questions
What is Emergent BioSolutions' free cash flow?
Emergent BioSolutions' free cash flow was $96.8M in Q3 2026 (third quarter 2026), +79% from Q2 2026.
How has Emergent BioSolutions' free cash flow changed?
Over the last 4 quarters it ranged from $54.0M (Q2 2026) to $104M (Q2 2025).